NEW YORK--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS) today announced that a series of three production runs of UCART19, its lead TALEN ® ...

SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...

Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...

Achievement allows IND-enabling studies in 1H 2023 and subsequent clinical testing of IMP761 to address root cause of autoimmune diseases Sydney, Australia, December 6, 2022 – Immutep Limited (ASX: ...

Based on the GMP-grade quality management system platform, combined with the production specifications of cell therapy drugs in various countries, we have successfully developed a series of ...

Colombian and Mexican GMP certifications expected during Q1'21 and Q2'21, respectively The Company confirms that its recently completed Processing and Extraction Center at its Rionegro facility, ...

BILTHOVEN, Netherlands and PARIS, March 22, 2022 /PRNewswire/ -- Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced the ...

MIAMI & TORONTO--(BUSINESS WIRE)--Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced ...